Evidence mapPaperPMID 41349559Full record

SynthesisThe Lancet. Infectious diseases2026

Best practice guidelines for viral hepatitis service delivery in prisons.

Yumi Sheehan, Akhil Garg, Julia Sheehan, Nonso Maduka, Frederick L Altice, Filipa Alves da Costa, Sean Cox, Ahmed M Elsharkawy, Ehab Salah, Mark Stoové and 7 more

Abstract readSystematic Review
In one paragraph

Synthesis in The Lancet. Infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Reimagining Hepatitis C Elimination: Time for Actions, Not Targets.Journal of the International AIDS Society · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yumi SheehanViral Immunology Systems Program, Kirby Institute, University of New South Wales, Sydney, NSW, Australia. Electronic address: ysheehan@kirby.unsw.edu.au.
Akhil GargDepartment of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montréal, QC, Canada.
Julia SheehanThe Hepatitis C Trust, London, UK.
Nonso MadukaBensther Development Foundation, Enugu, Nigeria.
Frederick L AlticeYale University, New Haven, CT, USA.
Filipa Alves da CostaWHO, Regional Office for Europe, Copenhagen, Denmark; Research Institutes for Medicines, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
Sean CoxThe Hepatitis C Trust, London, UK.
Ahmed M ElsharkawyLiver Unit and National Institute for Health and Care Research Biomedical Research Centre at University Hospitals Birmingham, Birmingham, UK.
Ehab SalahUN Office on Drugs and Crime, Vienna, Austria.
Mark StoovéBurnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne, VIC, Australia.
Lara TavoschiDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Alexander J ThompsonDepartment of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia; University of Melbourne, Melbourne, VIC, Australia.
Karla ThorntonUniversity of New Mexico School of Medicine, Albuquerque, NM, USA.
Andrew R LloydViral Immunology Systems Program, Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Joaquín CabezasGastroenterology and Hepatology Department, University Hospital Marques de Valdecilla, Santander, Spain; Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute, Santander, Spain.
Matthew J AkiyamaDepartment of Medicine, Albert Einstein College of Medicine, New York City, NY, USA; Montefiore Medical Centre, New York City, NY, USA.
Nadine KronfliDepartment of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montréal, QC, Canada; Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montréal, QC, Canada. Electronic address: nadine.kronfli@mcgill.ca.

Funding

NIDA NIH HHS K99 DA043011NIDA NIH HHS R00 DA043011NIDA NIH HHS R61 DA060627World Health Organization 001
6 · The paper itself

Abstract

Viral hepatitis constitutes a major health burden among people living in prison globally. There is poor access to prison-based viral hepatitis services, and people living in prison are rarely prioritised for care, undermining global elimination efforts. This Review is a narrative summary of the first Global Guidelines for Viral Hepatitis Service Delivery in Prisons, which included a systematic review and an expert-led GRADE process to develop best practice recommendations for viral hepatitis management in prisons. 703 articles were included, underpinning the development of 30 recommendations across eight domains: policy, testing, treatment, continuity of care, prevention and harm reduction, education, minority populations and special considerations, and monitoring and evaluation. Quality of evidence and strength of recommendations were rated as A1 (n=5), B1 (n=7), C1 (n=10), D1 (n=7), and expert opinion (n=1). The guidelines aim to standardise a global approach to prison-based viral hepatitis elimination efforts with consistent policy, practice, and reporting.

Indexed as

Hepatitis, Viral, HumanPractice Guidelines as TopicPrisonsHealth Services for PrisonersHumansPrisoners

Identifiers

PMID41349559
PMCPMC13333193

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.